Trophic action of sphingosine 1-phosphate in denervated rat soleus muscle.
Sphingosine 1-phosphate (S1P) mediates a number of cellular responses, including growth and proliferation. Skeletal muscle possesses the full enzymatic machinery to generate S1P and expresses the transcripts of S1P receptors. The aim of this work was to localize S1P receptors in rat skeletal muscle and to investigate whether S1P exerts a trophic action on muscle fibers. RT-PCR and Western blot analyses demonstrated the expression of S1P(1) and S1P(3) receptors by soleus muscle. Immunofluorescence revealed that S1P(1) and S1P(3) receptors are localized at the cell membrane of muscle fibers and in the T-tubule membranes. The receptors also decorate the nuclear membrane. S1P(1) receptors were also present at the neuromuscular junction. The possible trophic action of S1P was investigated by utilizing the denervation atrophy model. Rat soleus muscle was analyzed 7 and 14 days after motor nerve cut. During denervation, S1P was continuously delivered to the muscle through a mini osmotic pump. S1P and its precursor, sphingosine (Sph), significantly attenuated the progress of denervation-induced muscle atrophy. The trophic effect of Sph was prevented by N,N-dimethylsphingosine, an inhibitor of Sph kinase, the enzyme that converts Sph into S1P. Neutralization of circulating S1P by a specific antibody further demonstrated that S1P was responsible for the trophic effects of S1P during denervation atrophy. Denervation produced the down regulation of S1P(1) and S1P(3) receptors, regardless of the presence of the receptor agonist. In conclusion, the results suggest that S1P acts as a trophic factor of skeletal muscle.
Zanin
Marika
M
Department of Human Anatomy and Physiology, University of Padua, Padua, Italy.
Germinario
Elena
E
Dalla Libera
Luciano
L
Sandonà
Dorianna
D
Sabbadini
Roger A
RA
Betto
Romeo
R
Danieli-Betto
Daniela
D
D000818:Animals; D000906:Antibodies; D049108:Cell Enlargement; D002462:Cell Membrane / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006984:Hypertrophy; D015918:Infusion Pumps, Implantable; D008246:Lysophospholipids / Q000008:administration & dosage / Q000378:metabolism*; D008297:Male; D009121:Muscle Denervation; D018482:Muscle, Skeletal / Q000201:enzymology / Q000294:innervation / Q000378:metabolism* / Q000473:pathology; D009133:Muscular Atrophy / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D017570:MyoD Protein / Q000378:metabolism; D018008:Myogenin / Q000378:metabolism; D018995:Myosin Heavy Chains / Q000378:metabolism; D009469:Neuromuscular Junction / Q000378:metabolism; D009685:Nuclear Envelope / Q000378:metabolism; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D049349:Receptors, Lysosphingolipid / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D012584:Sciatic Nerve / Q000601:surgery; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D013997:Time Factors; D000099157:Sphingosine Kinase
D000906:Antibodies; D004791:Enzyme Inhibitors; D008246:Lysophospholipids; D017570:MyoD Protein; D018008:Myogenin; D018995:Myosin Heavy Chains; D017853:Phosphotransferases (Alcohol Group Acceptor); D012333:RNA, Messenger; D049349:Receptors, Lysosphingolipid; D013110:Sphingosine; D000099157:Sphingosine Kinase; C503803:Myog protein, rat; C060506:sphingosine 1-phosphate; C061800:N,N-dimethylsphingosine